Abstract:Cytochrome P450 3A4 (CYP3A4), a key enzyme, is pivotal in metabolizing approximately half of the drugs used clinically. The genetic polymorphism of the CYP3A4 gene significantly influences individual variations in drug metabolism, potentially leading to severe adverse drug reactions (ADRs). In this study, we conducted a genetic analysis on CYP3A4 gene in 1163 Chinese Han individuals to identify the genetic variations that might affect their drug metabolism capabilities. For this purpose, a multiplex polymerase chain reaction (PCR) amplicon sequencing technique was developed, enabling us to perform the genotyping of CYP3A4 gene efficiently and economically on a large scale. As a result, a total of 14 CYP3A4 allelic variants were identified, comprising six previously reported alleles and eight new nonsynonymous variants that were nominated as new allelic variants *39–*46 by the PharmVar Association. Further, functional assessments of these novel CYP3A4 variants were undertaken by coexpressing them with cytochromes P450 oxidoreductase (CYPOR) in Saccharomyces cerevisiae microsomes. Immunoblot analysis indicated that with the exception of CYP3A4.40 and CYP3A4.45, the protein expression levels of most new variants were similar to that of the wild-type CYP3A4.1 in yeast cells. To evaluate their catalytic activities, midazolam was used as a probe drug. The results showed that variant CYP3A4.45 had almost no catalytic activity, whereas the other variants exhibited significantly reduced drug metabolism abilities. This suggests that the majority of the CYP3A4 variants identified in the Chinese population possess markedly altered capacities for drug metabolism. SIGNIFICANCE STATEMENT In this study, we established a multiplex polymerase chain reaction (PCR) amplicon sequencing method and detected the maximum number of new CYP3A4 variants in a single ethnic population. Additionally, we performed the functional characterizations of these eight novel CYP3A4 allele variants in vitro. This study not only contributes to the understanding of CYP3A4 genetic polymorphism in the Chinese Han population but also holds substantial reference value for their potential clinical applications in personalized medicine.

Structure-Based Analysis of Cefaclor Pharmacokinetic Diversity According to Human Peptide Transporter-1 Genetic Polymorphism

Impurity Profile and Spectrum Characteristics of the Isomers in Cefamandole Nafate Using High- Performance Liquid Chromatography/high-Performance Size Exclusion Chromatography Tandem Ion Trap/time-of-flight Mass Spectrometry

Identification and Functional Assessment of EightCYP3A4Allelic Variants39–46Detected in the Chinese Han Population

The Influence of Genetic Polymorphisms in Drug Metabolism Enzymes and Transporters on the Pharmacokinetics of Different Fluvastatin Formulations

Effect of Cyp2d6 Genetic Polymorphism on the Metabolism of Citalopram in Vitro

Genetic Polymorphisms And In Silico Mutagenesis Analyses Of Cyp2c9, Cyp2d6, And Cypor Genes In The Pakistani Population

Identification And Functional Characterization Of New Potentially Defective Alleles Of Human Cyp2c19

Characterization of 15 CYP2J2 variants identified in the Chinese Han population on the metabolism of ebastine and terfenadine in vitro

Escitalopram population pharmacokinetics and remedial strategies based on CYP2C19 phenotype

Deep mutational scanning of CYP2C19 in human cells reveals a substrate specificity-abundance tradeoff

Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro

Population Pharmacokinetic Modeling of Cefepime, Meropenem, and Piperacillin-Tazobactam in Patients with Cystic Fibrosis

Genetic Variability in CYP3A5 and Its Possible Consequences

Structural and Functional Insights into CYP2C8.3: A Genetic Polymorph of Cytochrome P450 2C8

Characterizing the Effect of Cytochrome P450 (cyp)2c8, Cyp2c9, and Cyp2d6 Genetic Polymorphisms on Stereoselective N-Demethylation of Fluoxetine

Influence of novel CYP2C‐haplotype on proton pump inhibitor pharmacokinetics in children

Discovery and Enzyme Kinetic Characterization of Novel CYP2D6 Variants

Genetic polymorphism analysis of the drug-metabolizing enzyme CYP1A2 in a Uyghur Chinese population: a pilot study.

Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates

Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1

Functional analysis of nonsynonymous single nucleotide polymorphisms of multidrug resistance-associated protein 2 (ABCC2)